Shire's shares are on the run on the London Stock Exchange, pushed up by the new purchase offer presented by the US AbbVie, which increased the offer for the Irish pharmaceutical giant to £53,20 per share, compared to the £51,15 set on the plate last week. In this way the valuation of Shire rises up to 40 billion euros.
The Irish firm said it would recommend joining the offer. We are therefore moving towards the incorporation of Shire into AbbVie, to give life to a new global pharmaceutical giant. Upon completion of the transaction, Shire shareholders would come to own 25% of the new company.
